The therapeutic effect of pertuzumab on HER2 positive breast cancer patients and its effect on the expression of serum nectin-4 and TK-1
10.3760/cma.j.cn431274-20191230-01485
- VernacularTitle:帕妥珠单抗治疗HER2阳性乳腺癌患者的疗效及对血清nectin-4与TK-1表达的影响
- Author:
Yang ZHANG
;
Peng LI
;
Gang LIU
- From:
Journal of Chinese Physician
2021;23(1):72-76
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of pertuzumab in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients and its effect on the expression of serum nectin-4 and thymidine kinase 1 (TK-1).Methods:110 HER2 positive breast cancer patients treated in Longfu Hospital of Beijing from June 2014 to December 2016 were selected and divided into observation group and control group according to treatment method, 55 cases in each group.The control group was given docetaxel combined with platinum (TP) neoadjuvant chemotherapy, and the observation group was given TP neoadjuvant chemotherapy combined with paltuzumab. After 18 weeks of treatment, the therapeutic effect, serum tumor markers [carbohydrate antigen (CA), CA153 and CA199], immune function, levels of nectin-4 and TK-1 and adverse reactions were observed.Results:The total effective rate of the observation group was 83.64%(46/55), which was significantly higher than that of the control group 58.18%(32/55), with statistically significant difference ( P<0.05). After treatment, the levels of CA125, CA153 and CA199 in the two groups were decreased, and the difference was significant in the observation group ( P<0.05); after treatment, the levels of CD3 + , CD4 + , CD4 + /CD8 + in the two groups were increased, while the levels of CD8 + was decreased, with no significant difference between the two groups ( P>0.05). After treatment, the levels of serum nectin-4 and TK-1 decreased in both groups, and the the decrease in the observation group was significant ( P<0.05). There was no significant difference in digestive system, white blood cell count and cardiac toxicity between the two groups ( P>0.05). Two years follow-up showed that the mortality of the observation group was 3.64%(2/55), and that of the control group was 10.91%(6/55). The mortality of the group was significantly lower than that of the control group ( P<0.05). Conclusions:Pertuzumab combined with TP neoadjuvant chemotherapy has better effect on HER2 positive breast cancer patients, it can effectively inhibit the growth of tumor tissues, reduce the level of tumor markers and the level of nectin-4 and TK-1, and has less influence on the immune response of patients with fewer adverse reactions and lower mortality rate.
